Smell Loss After Viral Infection-nasal Steroids Actually Help?
- 01. What the evidence says
- 02. Why smell can drop (and linger)
- 03. Bottom-line answer (primary query)
- 04. Evidence at a glance
- 05. Numbers you can use
- 06. How to apply this (practical decision steps)
- 07. What "evidence" does NOT mean
- 08. How long to wait?
- 09. Safety and realistic expectations
- 10. FAQ
- 11. Reporting checklist (useful for readers)
Smell loss after a viral infection is common, and the best evidence suggests nasal steroids are not a universal fix-benefit depends on the cause, timing, and whether inflammation is still driving the problem. In post-viral olfactory dysfunction, intranasal corticosteroids may help some patients (especially when inflammation persists), but clinical trial data are mixed and often show smaller or inconsistent gains compared with combined strategies like olfactory training.
What the evidence says
After a viral infection, the sense of smell can drop because the olfactory epithelium and local inflammation are disrupted, and-in some infections-pathogen persistence and inflammatory signaling may matter. A systematic review discussing COVID-19 smell loss reports wide estimates of olfactory loss after infection and frames corticosteroids as potentially helpful by reducing inflammation and altering pathways involved in viral-host interactions, but it also emphasizes that there is no single, universally approved treatment for post-infectious anosmia.
When researchers compare topical (intranasal) steroids versus other approaches in postviral olfactory dysfunction, they often find the results are not consistently dramatic. A review of steroids and olfactory training for postviral smell disorders summarizes older case series and controlled comparisons where systemic steroids showed more improvement than topical steroids, and where one RCT reported better gains with olfactory training plus corticosteroids than with olfactory training alone.
Why smell can drop (and linger)
Olfactory dysfunction after a virus isn't one single disease state; it ranges from temporary irritation to longer-lasting dysfunction of odor detection and odor identification pathways. In COVID-19 specifically, research has reported viral persistence and inflammation in the olfactory epithelium and related brain infection in animal models, supporting a biologic rationale for anti-inflammatory treatment early in the course.
Clinically, the same complaint-"I lost my smell after a cold or COVID"-can come from different underlying mechanisms, which is why treatment response varies between people. This is also why many guidelines and evidence reviews focus on multimodal care: reducing nasal inflammation, restoring nasal airflow, and training the brain to relearn odor perception when possible.
Bottom-line answer (primary query)
Nasal steroids are supported as a reasonable anti-inflammatory option for some patients with post-viral smell loss, but the evidence does not guarantee recovery and is not uniform across studies. The strongest practical takeaway from the literature is that if inflammation-related drivers are present, steroids may help-yet many studies suggest the best outcomes come from combining steroid strategies with olfactory training rather than relying on intranasal steroids alone.
Evidence at a glance
| Condition/Population | Intervention | Study type | Reported effect direction | Source date (published) |
|---|---|---|---|---|
| Post-viral olfactory dysfunction (PVOD; includes multiple etiologies) | Topical vs systemic steroids | Non-randomized / summarized comparisons | Systemic tends to outperform topical in reported cohorts | 2004 (referenced in review) |
| COVID-19-related anosmia | Olfactory training (COT) vs COT + steroids | RCT summarized in review | Improvement larger with COT + steroids | 2021 (Le Bon et al., referenced in review) |
| Persistent smell loss after COVID-19 | Olfactory training + budesonide nasal irrigation | Cross-sectional study (pre/post design) | Improved TDI-related scores after 12 weeks | 2022 |
| General PVOD treatment landscape | Evidence-based review | Systematic review / evidence-based review | Optimized strategies depend on timing and combination care | 2020 |
Important: the table shows "effect direction" rather than a single universal success rate, because studies differ in populations, steroid types (e.g., systemic vs intranasal), timing, and outcome measures such as the Threshold-Discrimination-Identification (TDI) composite.
Numbers you can use
To interpret "does it work," you need to understand that measured outcomes vary, and studies use standardized smell tests like TDI. In the steroid/training evidence summary, one RCT cited in the review reported that patients receiving olfactory training plus steroids improved their olfactory score by 7.7 points on average (p = 0.007), compared with a 2.1-point increase in the olfactory training-only group (p = 0.126).
Also, post-infection smell loss estimates vary by infection and study design; the systematic review on corticosteroids and post-COVID-19 smell loss describes olfactory loss rates after COVID-19 reported between 4% and 89% across studies.
Finally, one published cross-sectional report (olfactory training plus budesonide irrigation over 12 weeks) describes significant improvement in overall TDI and detection threshold in their pre/post measurements (e.g., overall TDI p = 0.014; odor detection threshold p = 0.003), while odor discrimination and odor identification were not statistically significant in the same report (discrimination p = 0.08; identification p = 0.126).
How to apply this (practical decision steps)
When you're trying to decide whether to use nasal steroids, treat it like a structured clinical experiment: choose an evidence-aligned approach, monitor change with a consistent smell test or at-home proxy, and reassess if no improvement occurs. The evidence suggests that timing and combination with olfactory training are key variables, especially in COVID-era PVOD models and treatment summaries.
- Confirm the pattern: temporary reduced smell versus near-complete loss, and whether it's accompanied by congestion or chronic rhinosinusitis.
- Start with anti-inflammatory strategy if appropriate: intranasal corticosteroids are commonly used when inflammation is suspected, but results can be mixed if the cause is not predominantly inflammatory.
- Add olfactory training early when feasible: multiple reviews and trial summaries support better gains when training is paired with steroid approaches rather than used alone.
- Track outcomes consistently: use a standardized smell test when available (e.g., TDI-based assessment) or a structured at-home routine, and reassess at a clear time point (often weeks to a few months).
- Re-evaluate diagnosis if persistent: consider ENT evaluation for nasal pathology, medication effects, or alternative causes of anosmia/dysosmia.
What "evidence" does NOT mean
Smell loss is not a single endpoint where one therapy reliably works for everyone; different studies measure different outcomes, start treatment at different times, and enroll different severities of disease. Reviews emphasize that optimal management strategies in PVOD remain uncertain and that therapeutic response varies.
It's also easy to overinterpret "steroid helps" when the study actually includes olfactory training or other components alongside steroids. In the RCT summary, the incremental improvement was associated with the combined approach rather than steroids as a standalone intervention.
- Mixed efficacy: topical steroids may show smaller or inconsistent benefits compared with systemic approaches in some older cohorts.
- Combination strategy: training plus steroids shows stronger average improvement in at least one summarized RCT context for COVID-19 smell loss.
- Outcome sensitivity: TDI-related subcomponents (threshold vs discrimination vs identification) may respond differently.
- Timing matters: anti-inflammatory logic is more plausible when inflammatory drivers persist; biologic evidence supports ongoing inflammation and persistence in some contexts.
How long to wait?
Because PVOD can improve gradually, the key question is not only whether nasal steroids "work," but when you should judge whether they are helping enough to continue. Evidence summaries and studies commonly evaluate outcomes over weeks to months (e.g., 12 weeks in one budesonide + training report), which is consistent with the idea that smell recovery can be slow.
In the budesonide irrigation plus training report, the authors assessed improvement after a 12-week treatment period and found statistically significant improvements in overall TDI and odor detection threshold, suggesting that if there is a response, it may become measurable by that timeframe.
Safety and realistic expectations
Most intranasal steroid regimens used in routine ENT practice are generally considered low-risk compared with systemic steroids, but the exact safety profile depends on dose, device technique, and patient factors (e.g., nasal irritation, prior nasal surgery). The evidence you're asking about is focused on smell outcomes; it does not replace individualized clinician advice for dosing, contraindications, and monitoring.
A realistic expectation is therefore "possible partial improvement" rather than immediate full return of smell. The trial summary showing an average score increase of 7.7 points with combined therapy versus 2.1 points with training alone illustrates why people may feel a difference without necessarily returning to baseline quickly.
FAQ
Reporting checklist (useful for readers)
If you're scanning news coverage or social posts claiming a "cure," ask whether the claim refers to intranasal steroids alone, whether olfactory training was also used, and what outcome metric was measured. In the cited evidence summaries, the meaningful differences often appear in combined strategies and standardized smell scores rather than in casual self-report alone.
Example of what to look for: a claim might say "steroids help," but stronger evidence will specify test timing (e.g., around 12 weeks), the measured endpoint (e.g., TDI), and the comparator (e.g., training alone). In the summarized RCT context, the difference in average improvement (7.7 vs 2.1 points) illustrates the importance of a control arm when judging effect size.
Key concerns and solutions for Smell Loss After Viral Infection Nasal Steroids Actually Help
Do nasal steroids help after a viral infection causes smell loss?
They can help in some people because post-viral smell loss often involves inflammation, but the evidence is mixed and improvement is not guaranteed. Studies and reviews indicate that combining steroids with olfactory training generally performs better than training alone in at least some COVID-19 related contexts.
Is the best evidence specific to COVID-19?
Much of the detailed trial discussion focuses on COVID-19, but the broader concept of postviral olfactory dysfunction (PVOD) covers multiple viruses. Reviews on PVOD treatment strategies discuss variability and do not claim a universal steroid-only solution across all postviral causes.
Will I notice improvement quickly?
Not usually in days. In one report using budesonide nasal irrigation plus olfactory training, measurable improvements were assessed after 12 weeks, and earlier or faster changes are less consistently supported than gradual recovery.
Why do some studies show only partial improvements?
Smell tests break performance into components like threshold, discrimination, and identification, and therapies may improve some components more than others. In a 12-week budesonide irrigation plus training report, overall TDI and detection threshold improved significantly while discrimination and identification were not statistically significant in that dataset.
What should I do if my smell loss persists?
Consider an ENT evaluation to confirm the cause (e.g., persistent inflammation, nasal pathology, or other contributors) and to set a structured plan for therapy and monitoring. Evidence-based PVOD reviews emphasize that optimal strategies depend on the underlying drivers and that combination approaches are common.